Drug Database
XT

XTEN technology

✓ Approved

Amunix Pharmaceuticals, Inc. · 治疗药物

什么是 XTEN technology?

XTEN technology 是一种治疗药物,由Amunix Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

公司Amunix Pharmaceuticals, Inc.
给药途径Unknown
状态Approved

治疗适应症

XTEN technology 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedEnvironmental science & technology2026-11-17

Global Steel Decarbonization under Policy, Technology, and Resource Constraints: A Process-Unit Agent-Based Model.

Liu Xiao X, Hu Jingnan J, Liu Xingang X, Yuan Qiuling Q et al.

Deep decarbonization of steel requires low-emission technologies to be deployed through a long-lived and heterogeneous asset fleet without disrupting steel supply. We developed a country-resolved agent-based model that follows global steel process units annually from 2023 to 2060. Units choose among continued operation, renewal, retrofit, conversion, retirement, and new construction, subject to construction time, linked upstream capacity, national production pathways, and annual supplies of scrap, hydrogen, natural gas, and pellets. Four scenarios distinguish stronger climate policy from improved technology and resource availability. Global process-chain CO2 emissions decline by 67-79% by 2060, reaching 0.476-0.737 Gt. The integrated case achieves the lowest emissions, but the two-component interventions do not independently outperform the reference case. Stronger policy changes when assets enter a finite transition queue, whereas technology and material conditions determine whether replacement routes can be built and operated at that time. By 2060, Scrap-EAF supplies 74-80% of crude steel, but residual unabated blast furnaces and coal-based direct reduction keep national steel pathways above their allocated levels in many countries. Deep decarbonization, therefore, depends on coordinating asset turnover, construction, and complementary material systems, rather than on technology availability or carbon-price pressure alone.

PMID 43043249
阅读全文 →
PubMedNature2026-11-17

Can AI actually help the climate? Nations want to harness the technology to cut emissions.

Dinneen James J

PMID 43040017
阅读全文 →
PubMedExpert review of medical devices2026-11-17

Health on the move: exploring the potential use of medical device and digital health technology in travel medicine.

Liu Xiao Yu XY, Ganly Sandra S, Flaherty Gerard T GT

PMID 43042636
阅读全文 →
PubMedScientific American2026-11-17

The Escalating Backlash against Tech in Schools : States and school districts across the country are banning AI and limiting educational technology in classrooms.

Parshall Allison A

PMID 43043161
阅读全文 →
PubMedHCA healthcare journal of medicine2026-11-17

From Hired to Hands-On-Deck Status: Solving Delays in Health Care Hiring Processes and Supporting Workforce Safety Across a Large For-Profit Health System.

Skeens Cynthia C

During and after the COVID-19 pandemic, health care staffing shortages and onboarding inefficiencies, specifically delays in employee health clearance, prolonged time to hire, and threatened workplace and patient safety. An employee health onboarding workflow at a large health care organization was redesigned across 3 domains: people, process, and technology. Interventions included workflow standardization, elimination of non-value-added steps, optimized tuberculosis screening, increased appointment capacity, and technology integration (electronic health record [EHR] documentation, centralized scheduling and communication, and completion of pre-visit forms). Following a pilot from May to December 2022, the workflow was expanded organization-wide with a structured rollout and ongoing performance monitoring. During the May to December 2022 pilot, weekly visit capacity increased 158% (from 12 to 31 visits), mean visit duration decreased 77% (from 163 to 38 minutes), and paperwork time was reduced 50%. No hiring delays attributable to employee health processes occurred during the pilot or subsequent rollout. Targeted workflow redesign and technology integration significantly improved onboarding efficiency, reduced administrative burden, and enhanced operational performance. These findings support scalable, system-level strategies to streamline hiring, improve workforce readiness, and strengthen workplace and patient safety amid ongoing health care staffing demands.

PMID 43042169
阅读全文 →
PubMedSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026-11-17

[Innovations and Applications of Organoid Technology in Molecular Diagnostics].

Xue Zhifeng Z, Fu Xinyue X, Yang Runze R, Liu Yaling Y et al.

Organoid technology, a revolutionary three-dimensional stem cell culture model, can highly mimic the structure, cellular diversity, and physiological functions of human organs, offering a novel research paradigm for molecular diagnostics. Patient-derived organoids stably retain the genomic features, transcriptomic heterogeneity, and pathological phenotypes of their parental tissues during in vitro expansion and are hence recognized as "living biobanks." This review systematically summarizes the diverse applications of organoids in molecular diagnostics. At the genomic level, they enable the identification of driver mutations and the modeling of tumor clonal evolution and drug resistance mechanisms. In clinical translation, organoid drug sensitivity testing demonstrates potential for predicting individualized treatment responses and serves as an effective platform for biomarker discovery. Furthermore, the analysis of the organoid "secretome" provides a new avenue for identifying and functionally characterizing liquid biopsy biomarkers. In the study of infectious and genetic diseases, organoid models are used to elucidate pathogen-host interaction mechanisms and to provide functional evidence for validating pathogenic mutations in rare diseases. Although challenges remain in standardization and model complexity, the integration of single-cell multi-omics, gene editing, and bioengineering technologies is expected to establish organoid technology as a core tool spanning basic research through precision clinical diagnosis and treatment, thereby laying the foundation for personalized healthcare.

PMID 43041591
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多XTEN technology